Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 4, 2010, Pages 543-550

  Voykov, Bogomil ^a   Gelisken, Faik ^a   Inhoffen, Werner ^a   Voelker, Michael ^a   Ulrich Bartz Schmidt, Karl ^a   Ziemssen, Focke ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bevacizumab; Choroidal neovascularization; Pathologic myopia; Photodynamic therapy

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MYOPIA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 77949275238     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1285-1     Document Type: Article

References (37)

1. T Yoshida K Ohno-Matsui K Yasuzumi A Kojima N Shimada S Futagami, et al. 2003 Myopic choroidal neovascularization: a 10-year follow-up Ophthalmology 110 7 1297 1305 10.1016/S0161-6420(03)00461-5 12867382
2. K Ohno-Matsui T Yoshida 2004 Myopic choroidal neovascularization: natural course and treatment Curr Opin Ophthalmol 15 3 197 202 10.1097/01.icu. 0000120709.35941.e9 15118506
3. KJ Blinder MS Blumenkranz NM Bressler SB Bressler G Donato H Lewis, et al. 2003 Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3 Ophthalmology 110 4 667 673 10.1016/S0161-6420(02)01998-X 12689884
4. MJ Potter SM Szabo T Ho 2006 Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl Graefes Arch Clin Exp Ophthalmol 244 5 639 641 10.1007/s00417-005-0115-3 16175378
5. J Marticorena F Gomez-Ulla M Fernandez B Pazos MJ Rodriguez-Cid M Sanchez-Salorio 2006 Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularisation Am J Ophthalmol 142 2 335 337 10.1016/j.ajo.2006.03.003 1:CAS:528:DC%2BD28XnsFyltrg%3D 16876524
6. WM Chan TY Lai AL Wong DT Liu DS Lam 2007 Combined photodynamic therapy and triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study Br J Ophthalmol 91 2 131 133 10.1136/bjo.2006.103606
7. QD Nguyen S Shah S Tatlipinar DV Do EV Anden PA Campochiaro 2005 Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia Br J Ophthalmol 89 10 1368 1370 1:STN:280:DC%2BD2Mvps1Ohtw%3D%3D 16170134
8. I Yamamoto AH Rogers E Reichel PA Yates JS Duker 2007 Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia Br J Ophthalmol 91 2 157 160 10.1136/bjo.2006.096776 16870653
9. H Sakaguchi Y Ikuno F Gomi M Kamei M Sawa M Tsujikawa, et al. 2007 Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia Br J Ophthalmol 91 2 161 165 10.1136/bjo.2006.099887 1:STN:280:DC%2BD2s%2FktlagsA%3D%3D 16914470
10. Chan WM, Lai TY, Liu DT, Lam DS (2008) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br J Ophthalmol 2008
11. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147(1):84-93 e1
12. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147(1):94-100 e1
13. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1 (2001) Ophthalmology 108(5):841-52
14. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Hara W, Yoshida T, et al (2009) Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol
15. ML Hernandez-Rojas H Quiroz-Mercado J Dalma-Weiszhausz J Fromow-Guerra A Amaya-Espinosa A Solis-Vivanco, et al. 2007 Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia Retina 27 6 707 712 17621179
16. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, Fernandez M (2009) Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye (Lond) 23(2):334-8
17. Wu PC, Chen YJ (2009) Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye
18. RM Silva JM Ruiz-Moreno J Nascimento A Carneiro P Rosa A Barbosaa, et al. 2008 Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization Retina 28 8 1117 1123 10.1097/IAE.0b013e31817eda41 18788102
19. MD Bennett W Yee 2007 Pegaptanib for myopic choroidal neovascularization in a young patient Graefes Arch Clin Exp Ophthalmol 245 6 903 905 10.1007/s00417-006-0472-6 17115175
20. YS Chen JY Lin SY Tseng SG Yow WJ Hsu SC Tsai 2007 Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up Retina 27 7 839 845 10.1097/IAE.0b013e31804b1e6f 17891006
21. K Hayashi K Ohno-Matsui S Teramukai N Shimada M Moriyama W Hara, et al. 2008 Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls Am J Ophthalmol 145 3 518 526 10.1016/j.ajo.2007.10.032 1:CAS:528: DC%2BD1cXitVWqs7w%3D 18207125
22. RF Spaide K Laud HF Fine JM Klancnik Jr CB Meyerle LA Yannuzzi, et al. 2006 Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 4 383 390 10.1097/00006982-200604000-00001 16603955
23. ZF Bashshur A Bazarbachi A Schakal ZA Haddad CP El Haibi BN Noureddin 2006 Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 142 1 1 9 10.1016/j.ajo.2006.02.037 1:CAS:528:DC%2BD28Xms1GktLg%3D 16815245
24. A Kojima K Ohno-Matsui S Teramukai Y Ishihara N Shimada T Yoshida, et al. 2006 Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia Graefes Arch Clin Exp Ophthalmol 244 11 1474 1479 10.1007/s00417-006-0324-4 16628418
25. D Wong KK Li 2008 Avastin in myopic choroidal neovascularisation: is age the limit? Br J Ophthalmol 92 8 1011 1012 10.1136/bjo.2007.135681 18653589
26. EJ Chung HJ Koh 2007 Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection Korean J Ophthalmol 21 3 185 187 10.3341/kjo.2007.21.3.185 17804928
27. WM Chan TY Lai DT Liu DS Lam 2007 Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study Ophthalmology 114 12 2190 2196 10.1016/j.ophtha.2007.03.043 17599414
28. M Luke M Warga F Ziemssen F Gelisken S Grisanti T Schneider, et al. 2006 Effects of bevacizumab on retinal function in isolated vertebrate retina Br J Ophthalmol 90 9 1178 1182 10.1136/bjo.2006.094995 1:STN:280: DC%2BD28rgsVShsQ%3D%3D 16754646
29. F Ziemssen M Luke A Messias J Beutel O Tatar E Zrenner, et al. 2008 Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients Int Ophthalmol 28 2 101 109 10.1007/s10792-007-9122-1 17634860
30. L Arias N Planas S Prades JM Caminal M Rubio O Pujol, et al. 2008 Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results Br J Ophthalmol 92 8 1035 1039 10.1136/bjo.2007.130260 1:STN:280:DC%2BD1cvnsVOgtQ%3D%3D 18653595
31. S Mandal P Venkatesh R Sampangi S Garg 2007 Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization Eur J Ophthalmol 17 4 620 626 1:STN:280:DC%2BD2svltlKisw%3D%3D 17671940
32. Yodoi Y, Tsujikawa A, Nakanishi H, Otani A, Tamura H, Ojima Y, et al (2009) Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 147(5):816-24, 824 e1
33. LK Chang RF Spaide C Brue KB Freund JM Klancnik Jr JS Slakter 2008 Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration Arch Ophthalmol 126 7 941 945 10.1001/archopht.126.7.941 1:CAS:528:DC%2BD1cXptFymu7w%3D 18625940
34. Dithmar S, Schaal KB, Hoh AE, Schmidt S, Schutt F (2008) [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia.]. Ophthalmologe 28.
35. Sayanagi K, Ikuno Y, Soga K, Wakabayashi T, Tano Y (2009) Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol 87(4):460-3
36. F Rensch UH Spandau F Schlichtenbrede S von Baltz T Libondi JB Jonas, et al. 2008 Intravitreal bevacizumab for myopic choroidal neovascularization Ophthalmic Surg Lasers Imaging 39 3 182 185 10.3928/15428877-20080501-14 18556936
37. MA Rheaume M Sebag 2008 Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia Can J Ophthalmol 43 5 576 580 10.3129/I08-104 18982035